Research and Markets: Central Nervous System - Alzheimer Disease Drug Pipeline Report
Posted on: Monday, 16 July 2007, 15:03 CDT
Research and Markets (http://www.researchandmarkets.com/reports/c62852) has announced the addition of Central Nervous System - Alzheimer Disease Drug Pipeline Report to their offering.
"Central Nervous System - Alzheimer Disease Drug Pipeline Report" contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of Alzheimer disease drugs by company and by stage as well as a summary of the latest news and developments in this area.
Scope of the report:
Each Therapy Area Pipeline Report provides the user with real detail on drug pipelines, by company and by stage, for each specific therapy area. The latest news, by company, also ensures that each report is fresh and up-to-date.
In addition to new developments and disease specific pipeline projects, each report also contains extensive information in tabular format on a company's full product pipeline and products by phase of development with regard to the therapy area.
Full pipeline details, by stage, are provided and include detailed product descriptions, information on partnering activity plus clinical trial intelligence. Each Therapy Area Pipeline Report also provides detail on the top 20 companies with products in the early stage of development and the top 20 companies with products in the late stage of development. Finally, each report also provides a comparison with other major indications in the disease hub based on Marketed Products vs. Pipeline Products.
Key benefits
- Understand a company's strategic position by accessing detailed independent intelligence on its product pipeline for specific therapy areas.
- Keep track of your competitors and partners by better understanding their product pipeline.
- Monitor a company's research effectiveness by determining pipeline depth and number of products in development by clinical phase for specific disease areas.
- Maintain a critical competitive advantage.
Content Outline:
RECENT HIGHLIGHTS AND CHANGES
--Recent Highlights and Changes
UPCOMING PATENT EXPIRES BY THERAPY AREA
Alzheimer Disease Pipeline Overview
--% of Projects (By Phase of Development)
--No. of Projects by Phase of Development
--Marketed Products Vs. Pipeline Products
Company Overview - Pipeline Projects
--Company Overview - Pipeline Projects
--Legend
--Top 20 companies in late stage Alzheimer Disease Projects
--Top 20 companies in early stage Alzheimer Disease Projects
Full Pipeline View
--Pre Clinical Pipeline View
--Phase I Pipeline View
--Phase II Pipeline View
--Phase III Pipeline View
--Approved Pipeline View
For more information visit http://www.researchandmarkets.com/reports/c62852
Source: Life Science Analytics
Source: Business Wire
Related Articles
- Alzheimer's Drug Development Summit: CBI to Donate Portion of This Week's Proceeds to the Alzheimer's Association
- New Test Could Detect Early Stages Of Alzheimer’s
- Cancer - Gastrointestinal (Stomach) Cancer Report Provides The User With Real Detail On Drug Pipelines, By Company And By Stage
- AMT Obtains License to Amgen's GDNF Gene to Develop Treatment for Parkinson's Disease With AMT's Proprietary Gene Therapy Platform
- Samaritan Presents Favorable Caprospinol Data At Alzheimer's Drug Development Summit November 30
- Silver Dragon Completes Phase 1 of Its Exploration and Development Program for the Erbahuo Silver Mine
- Central Nervous System Stroke Drug Pipeline Report Provides the User With Real Details on Stroke Drug Pipelines By Company and By Stage
- Wave Systems' Secure Enterprise Software and Server Products to Be Demonstrated at the Intel Developer Forum, Booth 943, August 23-25, Moscone Center West, San Francisco
- Myriad Genetics Phase 3 Trial in Alzheimer's Disease is Proceeding on Schedule
- Russia, Sweden To Enact Clean Production Project
 |
 |
User Comments (0)
RSS Feeds